Immatics股票讨论区

$Immatics(IMTX.US)$ Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For ACTengine IMA203 TCR-T Monotherapy

$Immatics(IMTX.US)$近3年营收均增长，但增速下降很快，2021年仅有11%，营业利润随营收增长而亏损加大。
2022前3季度营收增长6倍，营业利润达到0.3亿，净利润则由于出售股权收益达到了0.5亿。
目前市盈率TTM 16，但是盈利数据太少，可以多等几个季度再判断。

Gapping up
News:
• $PyroGenesis Canada(PYR.US)$ +5.9% (announces that the negotiation for the land-based system to destroy PFAS contract has been suspended and discontinued)
• $Immatics(IMTX.US)$ +3.1% (announces a clinical data update for the IMA203)
• $iPATH 标普500 VIX短期期货ETN(VXX.US)$ +1.6% (rising with softness in futures)
• $Nevro(NVRO.US)$ +1.4% (comments on $联合健康(UNH.US)$ medical coverage policy u...

Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA生物科学(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...

$Immatics(IMTX.US)$ 音量太小了

$Immatics(IMTX.US)$ over take. $25

$IMTX — STOCK PLAY
key indicator for MORE uptrend $18.08
confirmation uptrend - $18.97
mini breakout - $19.30
full breakout - $22.02
stop loss & support - $14.11 $Immatics(IMTX.US)$

$Immatics(IMTX.US)$入